CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106. A total of 78 filers reported holding CUE BIOPHARMA INC in Q2 2023. The put-call ratio across all filers is 0.49 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $40,586 | -37.0% | 17,646 | 0.0% | 0.00% | – |
| Q2 2023 | $64,408 | +7.3% | 17,646 | +41.9% | 0.00% | – |
| Q1 2022 | $60,000 | -57.7% | 12,437 | -1.1% | 0.00% | – |
| Q4 2021 | $142,000 | -23.7% | 12,581 | -1.4% | 0.00% | – |
| Q3 2021 | $186,000 | -70.1% | 12,763 | -71.0% | 0.00% | – |
| Q1 2020 | $623,000 | -33.5% | 43,944 | -25.5% | 0.00% | – |
| Q4 2019 | $937,000 | – | 58,994 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Corriente Advisors, LLC | 820,000 | $11,636,000 | 12.56% |
| Prosight Management, LP | 552,060 | $7,834,000 | 3.66% |
| Nantahala Capital Management | 2,503,840 | $35,529,000 | 1.33% |
| MANGROVE PARTNERS IM, LLC | 601,398 | $8,534,000 | 1.18% |
| Voss Capital, LLC | 88,670 | $749,000 | 1.00% |
| Slate Path Capital LP | 870,694 | $12,355,000 | 0.95% |
| Avoro Capital Advisors LLC | 1,870,000 | $26,535,000 | 0.90% |
| Bleichroeder LP | 165,000 | $2,341,000 | 0.61% |
| 683 Capital Management, LLC | 640,000 | $9,082,000 | 0.54% |
| PA Capital LLC | 40,706 | $578,000 | 0.51% |